8-K
filed May 11, 2023, 7:59 PM ET
ticker BRNS
CIK 0001828185
other
confidence high
sentiment neutral
materiality 0.10
Vaccitech shareholders approve all proposals at 2023 AGM
Barinthus Biotherapeutics plc.
- Re-elected directors Karen T. Dawes (18.8M for) and Anne M. Phillips (19.7M for).
- Re-appointed PricewaterhouseCoopers LLP as UK statutory auditors (19.7M for).
- Ratified PwC as independent registered public accounting firm for FY2023 (19.7M for).
- Approved advisory vote on directors' compensation report (19.7M for).
- Received annual accounts for FY2022; no dividend recommended (19.7M for).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Barinthus Biotherapeutics plc. shareholders approved To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association at the 2023-05-11 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-11
Exact text from the filing
Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Barinthus Biotherapeutics plc. shareholders approved To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association at the 2023-05-11 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-11
Exact text from the filing
Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Barinthus Biotherapeutics plc. shareholders approved To receive and approve on an advisory basis the Company’s U.K. statutory directors’ compensation report for the fiscal year ended December 31, 2022, which is set forth in Annex A to the Company’s proxy statement at the 2023-05-11 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-11
Exact text from the filing
Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Barinthus Biotherapeutics plc. shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-11 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-11
Exact text from the filing
Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Barinthus Biotherapeutics plc. shareholders approved To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to note that the Company’s directors do not recommend the payment of any dividend for the fiscal year ended December 31, 2022 at the 2023-05-11 meeting.
- Outcome
- passed
- Meeting
- 2023-05-11
Exact text from the filing
Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Barinthus Biotherapeutics plc. shareholders approved To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders at the 2023-05-11 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-11
Exact text from the filing
Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Barinthus Biotherapeutics plc. shareholders approved To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 at the 2023-05-11 meeting.
- Outcome
- passed
- Meeting
- 2023-05-11
Exact text from the filing
Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.